All for Joomla All for Webmasters

Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening

Rate this item
(0 votes)

Utility:

This study looked at anti-RNA polymerase III antibodies (anti-RNAP3). Three studies conducted (1) The EUSTAR database was analyzed to identify 4986 patients with anti-RNAP3 status information. Anti-RNAP3 was associated with renal crisis and diffuse cutaneous involvement. (2) Case-control study where 158 anti-RNAP3+ cases were compared with 199 local anti-RNAP3? controls at SSc onset. The results showed that anti-RNP3 was associated with gastric antral vascular ectasia, rapid progression of skin involvement, and malignancies concomitant to SSc onset. (3) A Delphi exercise was performed by 82 experts to reach consensus for cancer screening in anti-RNAP3+ patients. The Delphi exercise highlighted the need for malignancy screening at the time of diagnosis for anti-RNP3+ patients and tight follow-up in the following years. The overall conclusion of the three studies was that anti-RNAP3+ patients with SSc have a high risk of concomitant malignancy. These results have implications for clinical practice and suggest regular screening for cancer in anti-RNAP3+ patients
Read 142 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection